Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease

This study was designed to test the interaction between amyloid-β and tau proteins as a determinant of metabolic decline in preclinical Alzheimer's disease (AD). We assessed 120 cognitively normal individuals with [(18)F]florbetapir positron emission tomography (PET) and cerebrospinal fluid (CS...

Descripción completa

Detalles Bibliográficos
Autores principales: Pascoal, T A, Mathotaarachchi, S, Mohades, S, Benedet, A L, Chung, C-O, Shin, M, Wang, S, Beaudry, T, Kang, M S, Soucy, J-P, Labbe, A, Gauthier, S, Rosa-Neto, P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5262471/
https://www.ncbi.nlm.nih.gov/pubmed/27021814
http://dx.doi.org/10.1038/mp.2016.37

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5262471/
https://www.ncbi.nlm.nih.gov/pubmed/27021814
http://dx.doi.org/10.1038/mp.2016.37

Ejemplares similares